that Ariad contends provided the jury with substantial evidence relating to each of the three classes of molecules, and we deem them insufficient as a matter of law. Indeed, most of the testimony cited by Ariad was irrelevant to the question whether the inventors were in possession of the claimed invention as of the 1989 priority date. The '516 patent discloses no w scope of the right to exclude” must not “overreach the scope of the inventor’s contribution to the field of art as described in the patent specification”); Fiers, 984 F.2d at 1171 (“Claiming all DNA[s] that achieve a result without defining what means will do so is not in compliance with the description requirement; it is an attempt to preempt the future before it has arrived.”); cf. Carnegie Mellon, 541 F.3d at 1126 (<HOLDING>). Here, the specification at best describes
recognizing that the supremacy clause is not a source of any federal rights holding that the language of the arbitration clause   any controversy or claim arising out of     was broad enough to encompass the plaintiffs claim alleging fraud in the inducement of the contract holding estoppel claim could not lie in tort where the facts that support the claim could not support a claim for fraud or misrepresentation holding that the narrow description of the e coli pola gene did not adequately support a broad claim to the gene from any bacterial source holding a broad claim with no factual support was insufficient to satisfy rule 9b